search
Back to results

In Vivo Alzheimer Proteomics (PROMARA)

Primary Purpose

Probable Alzheimer Disease, Parkinson Disease, Neurological Disease Without Cognitive Degradation

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
administration of stable isotope-labelled leucine-
collection of CSF, blood, urine, saliva
Sponsored by
University Hospital, Montpellier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Probable Alzheimer Disease focused on measuring Alzheimer disease (AD), diagnosis biomarkers, cerebrospinal fluid (CSF), targeted quantitative proteomics, mass spectrometry, stable isotope-labelled leucine

Eligibility Criteria

55 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Reports written consent, informed and signed by the patient and a trusted person
  • Subject member or beneficiary of a social security system

Specific criteria for group 1 and 2B :

  • Age between 55 and 85 years old for patients
  • Subject with AD or other neurodegenerative disease (frontotemporal dementia, dementia with Lewy bodies, Parkinson disease)
  • Subjects with chronic adult hydrocephalus (HCA) requiring depletion lumbar puncture (PL)

Specific criteria for group 2A :

- Adult patient requiring neurosurgery with CSF shunt (subject with brain trauma, acute hydrocephaly) and favorable evolution that allows removal of the shunt

Exclusion Criteria:

  • Patient deprived of liberty by judicial or administrative decision
  • Major protected by law
  • Pregnancy, women of childbearing age with risk of pregnancy, or breast-feeding
  • Presence of a transmissible viral disease (HlV, hepatitis B and C)
  • Patient included in a clinical trial
  • lnadequate cardiac, hepatic or severe renal disfunction
  • Disease amino acid metabolism (Leucinose..)

Exclusion Criteria:

  • Information clinical and para-clinical insufficient or unavailable
  • Patient deprived of liberty by judicial or administrative decision
  • Major protected by law
  • Pregnancy, women of childbearing age with risk of pregnancy, or breast
  • feeding
  • Presence of a transmissible viral disease (HIV, hepatitis B and C)
  • Patient included in a clinical trial
  • Patient exclusion period relative to another protocol or for which the maximum annual compensation of 4500€ has been reached
  • Inadequate cardiac, hepatic or severe renal
  • Disease amino acid metabolism (Leucinose..)

Sites / Locations

  • Laboratoire de Biochimie et Protéomique Clinique, CHU Montpellier

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Group 1

Group 2A

Group 2B

Arm Description

60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)

20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF

30 patients (15 probable AD, 15 neurological disease without cognitive degradation)

Outcomes

Primary Outcome Measures

C13 Leucine incorporation in Amyloid peptides (1-40, 1-42) at different time points (in %)
Analysis of labelled samples with mass spectrometry. Data generated will be studied to validate the experimental model and understand the pathophysiology of neurological disorders. A collection of labelled biological samples will also be generated.
C13 Leucine incorporation in detectable peptides generated after trypsin digestion of biological fluids from patients (CSF, blood, urine, saliva) (in %)
C13 Leucine incorporation in detectable peptides generated after trypsin digestion of biological fluids from patients (CSF, blood, urine, saliva) (in %)

Secondary Outcome Measures

Full Information

First Posted
September 18, 2014
Last Updated
December 27, 2021
Sponsor
University Hospital, Montpellier
Collaborators
Assistance Publique - Hôpitaux de Paris, University Hospital, Clermont-Ferrand, International Atomic Energy Agency
search

1. Study Identification

Unique Protocol Identification Number
NCT02263235
Brief Title
In Vivo Alzheimer Proteomics
Acronym
PROMARA
Official Title
Use of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer Disease
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Terminated
Why Stopped
end of the inclusion period
Study Start Date
October 8, 2013 (Actual)
Primary Completion Date
May 22, 2018 (Actual)
Study Completion Date
May 22, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
Collaborators
Assistance Publique - Hôpitaux de Paris, University Hospital, Clermont-Ferrand, International Atomic Energy Agency

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In France, an estimated 860 000 patients are affected by Alzheimer Disease (AD) which represents, as in other developed countries, a major public health issue. In many cases, AD diagnosis is uncertain and its clinical evolution unpredictable. The exactitude of the diagnosis is however particularly important in the perspective of the validation and use of new therapeutic strategies in AD. Detection of cerebrospinal fluid (CSF) diagnosis biomarkers fell short in the detection, of atypical/mixed cases, of some differential diagnosis, and in differentiating rapid or slow clinical evolutions. Hence, CSF analysis gives a unique opportunity to detect and validate biomarkers in many neurological disorders. Nevertheless, in medical practice, CSF biological analysis is currently limited to a small number of analytes.Quantitative and targeted mass spectrometry, especially operated in the Multiple reaction monitoring mode (MRM), represents an alternative to immunodetection and could be used to detect specific biomarkers in complex matrices such as plasma by specifically discriminating the proteotypic peptides corresponding to each proteins. Mass spectrometry has also the ability to distinguish and quantify isotopically labelled and unlabeled selected targets. This ability was used in a publication by the group of R. Bateman (Washington University, St Louis, USA) who could, after administering stable isotope-labelled leucine, evaluate Ab synthesis and clearance in humans. This approach has an enormous potential to study the metabolism of proteins within the human CNS and consequently help in the understanding and diagnosis of neurological disorders.The main objective of this program is set up a targeted quantitative mass spectrometry method for existing and stable isotope-labelled CSF biomarkers in the neurological field; exploit this approach for diagnostic purpurses and to gain knowledge in the pathophysiology of diseases.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Probable Alzheimer Disease, Parkinson Disease, Neurological Disease Without Cognitive Degradation, Brain Trauma, Acute Hydrocephaly
Keywords
Alzheimer disease (AD), diagnosis biomarkers, cerebrospinal fluid (CSF), targeted quantitative proteomics, mass spectrometry, stable isotope-labelled leucine

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
89 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1
Arm Type
Experimental
Arm Description
60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)
Arm Title
Group 2A
Arm Type
Experimental
Arm Description
20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF
Arm Title
Group 2B
Arm Type
Experimental
Arm Description
30 patients (15 probable AD, 15 neurological disease without cognitive degradation)
Intervention Type
Biological
Intervention Name(s)
administration of stable isotope-labelled leucine-
Intervention Description
- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
Intervention Type
Other
Intervention Name(s)
collection of CSF, blood, urine, saliva
Intervention Description
- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
Primary Outcome Measure Information:
Title
C13 Leucine incorporation in Amyloid peptides (1-40, 1-42) at different time points (in %)
Description
Analysis of labelled samples with mass spectrometry. Data generated will be studied to validate the experimental model and understand the pathophysiology of neurological disorders. A collection of labelled biological samples will also be generated.
Time Frame
1.5 years
Title
C13 Leucine incorporation in detectable peptides generated after trypsin digestion of biological fluids from patients (CSF, blood, urine, saliva) (in %)
Description
C13 Leucine incorporation in detectable peptides generated after trypsin digestion of biological fluids from patients (CSF, blood, urine, saliva) (in %)
Time Frame
1.5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Reports written consent, informed and signed by the patient and a trusted person Subject member or beneficiary of a social security system Specific criteria for group 1 and 2B : Age between 55 and 85 years old for patients Subject with AD or other neurodegenerative disease (frontotemporal dementia, dementia with Lewy bodies, Parkinson disease) Subjects with chronic adult hydrocephalus (HCA) requiring depletion lumbar puncture (PL) Specific criteria for group 2A : - Adult patient requiring neurosurgery with CSF shunt (subject with brain trauma, acute hydrocephaly) and favorable evolution that allows removal of the shunt Exclusion Criteria: Patient deprived of liberty by judicial or administrative decision Major protected by law Pregnancy, women of childbearing age with risk of pregnancy, or breast-feeding Presence of a transmissible viral disease (HlV, hepatitis B and C) Patient included in a clinical trial lnadequate cardiac, hepatic or severe renal disfunction Disease amino acid metabolism (Leucinose..) Exclusion Criteria: Information clinical and para-clinical insufficient or unavailable Patient deprived of liberty by judicial or administrative decision Major protected by law Pregnancy, women of childbearing age with risk of pregnancy, or breast feeding Presence of a transmissible viral disease (HIV, hepatitis B and C) Patient included in a clinical trial Patient exclusion period relative to another protocol or for which the maximum annual compensation of 4500€ has been reached Inadequate cardiac, hepatic or severe renal Disease amino acid metabolism (Leucinose..)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sylvain Lehmann, PU-PH
Organizational Affiliation
Laboratoire de Biochimie et Protéomique Clinique, IRMB St Eloi, CHRU de Montpellier
Official's Role
Principal Investigator
Facility Information:
Facility Name
Laboratoire de Biochimie et Protéomique Clinique, CHU Montpellier
City
Montpellier
ZIP/Postal Code
34295
Country
France

12. IPD Sharing Statement

Learn more about this trial

In Vivo Alzheimer Proteomics

We'll reach out to this number within 24 hrs